[Value of a defibrinating agent in potentiating therapeutic thrombolysis in severe pulmonary embolism].
D000368:Aged; D012103:Batroxobin / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D004357:Drug Synergism; D005260:Female; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000008:administration & dosage*; D010447:Peptide Hydrolases / Q000008:administration & dosage*; D010958:Plasminogen / Q000008:administration & dosage*; D011655:Pulmonary Embolism / Q000188:drug therapy*; D011897:Random Allocation; D013997:Time Factors; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage*
D010446:Peptide Fragments; C018998:lysyl-plasminogen; D010958:Plasminogen; D006493:Heparin; D010447:Peptide Hydrolases; D012103:Batroxobin; D014568:Urokinase-Type Plasminogen Activator
Intérêt d'un agent défibrinant pour potentialiser une thrombolyse thérapeutique dans les embolies pulmonaires sévères.